Physician profile
David Michael Ryan
NPI 1912918129
$14,436.79
in general payments reported to CMS, 2019-2025
52 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $1,709 · 2021: $2,102 · 2022: $3,025 · 2023: $2,272 · 2024: $2,078 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,194 · Education: $0.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,193.89 |
| Education | $0.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,002.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,484.42 | 2019-2025 | Ubrelvy, Creon, Qulipta |
| Pfizer INC. | $1,173.96 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $888.35 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $840.02 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $809.44 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $698.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $612.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $444.61 | 2021-2024 | |
| Amgen INC. | $345.85 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $325.59 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $312.37 | 2021-2024 | Qelbree, Qelbree |
| Esperion Therapeutics, INC. | $300.19 | 2020-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $231.98 | 2021-2024 | Spravato |
| Allergan, INC. | $221.67 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.